Metyrapone/oxazepam - Embera

Drug Profile

Metyrapone/oxazepam - Embera

Alternative Names: EMB 001C; EMB-001

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator Louisiana State University
  • Developer Embera NeuroTherapeutics
  • Class Antidepressants; Antihormones; Anxiolytics; Benzodiazepinones; Pyridines
  • Mechanism of Action GABA A receptor agonists; Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cocaine abuse

Highest Development Phases

  • Phase I Cocaine abuse; Smoking withdrawal

Most Recent Events

  • 26 Jul 2016 Embera NeuroTherapeutics plans a phase II trial for Cocaine abuse
  • 01 Jul 2016 Embera NeuroTherapeutics in collaboration with the National Institute on Drug Abuse initiate a phase I trial in Cocaine abuse in USA (NCT02856854)
  • 07 Jan 2016 Embera NeuroTherapeutics completes a phase I trial in Smoking withdrawal (In volunteers) in USA (PO) (NCT02406066)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top